Praxis Pushes Ulixacaltamide Into Phase III For Essential Tremor, But Uncertainty Remains

 
• By Alaric DeArment
Praxis announced results from its Phase II study in essential tremor • Source: Shutterstock

More from Clinical Trials

More from R&D